124 results on '"Kageji T"'
Search Results
2. Correlation between radiation dose and histopathological findings in patients with gliblastoma treated with boron neutron capture therapy (BNCT)
- Author
-
Kageji, T., Mizobuchi, Y., Nagahiro, S., Nakagawa, Y., and Kumada, H.
- Published
- 2014
- Full Text
- View/download PDF
3. Clinical results of boron neutron capture therapy (BNCT) for glioblastoma
- Author
-
Kageji, T., Mizobuchi, Y., Nagahiro, S., Nakagawa, Y., and Kumada, H.
- Published
- 2011
- Full Text
- View/download PDF
4. Boron neutron capture therapy combined with fractionated photon irradiation for glioblastoma: A recursive partitioning analysis of BNCT patients
- Author
-
Nakai, K., Yamamoto, T., Aiyama, H., Takada, T., Yoshida, F., Kageji, T., Kumada, H., Isobe, T., Endo, K., Matsuda, M., Tsurubuchi, T., Shibata, Y., Takano, S., Mizumoto, M., Tsuboi, K., and Matsumura, A.
- Published
- 2011
- Full Text
- View/download PDF
5. Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT)
- Author
-
Kageji, T., Mizobuchi, Y., Nagahiro, S., Nakagawa, Y., and Kumada, H.
- Published
- 2011
- Full Text
- View/download PDF
6. Cost analysis of radiotherapy, carbon ion therapy, proton therapy and BNCT in Japan
- Author
-
Nakagawa, Y., Yoshihara, H., Kageji, T., and Matsuoka, R.
- Published
- 2009
- Full Text
- View/download PDF
7. New support system using a mobile device for diagnostic image display and treatment of acute stroke in Japanese depopulated areas
- Author
-
Kageji, T, Oka, H, Obata, F, Tani, K, Bando, H, Tabata, R, and Kohno, M
- Published
- 2014
- Full Text
- View/download PDF
8. Introduction of the Kaifu telemedicine system for emergency medicine to ambulance services with improvement of the survival rates
- Author
-
Obata, F, Tabata, R, Mori, K, Kageji, T, Tani, K, and Bando, H
- Published
- 2014
- Full Text
- View/download PDF
9. An aspergillotic aneurysm of the internal carotid artery following allogeneic bone marrow transplantation: successful management with catheter coil embolization and long-term antifungal agents
- Author
-
Watanabe, T., Okada, T., Okada, C., Onishi, T., Watanabe, H., Okamoto, Y., Kitamura, Y., Manabe, S., Matsubara, S., Kageji, T., and Iwai, A.
- Published
- 2009
- Full Text
- View/download PDF
10. High-resolution nuclear track mapping in detailed cellular histology using CR-39 with the contact microscopy technique
- Author
-
Amemiya, K., Takahashi, H., Kajimoto, Y., Nakazawa, M., Yanagie, H., Hisa, T., Eriguchi, M., Nakagawa, Y., Majima, T., Kageji, T., Sakurai, Y., Kobayashi, T., Konishi, T., Hieda, K., Yasuda, N., and Ogura, K.
- Published
- 2005
- Full Text
- View/download PDF
11. Pleomorphic xanthoastrocytoma: a comparative pathological study between conventional and anaplastic types
- Author
-
Hirose, T, Ishizawa, K, Sugiyama, K, Kageji, T, Ueki, K, and Kannuki, S
- Published
- 2008
12. Multiple cystic cavernous angiomas associated with hemorrhage
- Author
-
Yagi, K., Kageji, T., Nagahiro, S., and Murayama, Y.
- Published
- 2005
- Full Text
- View/download PDF
13. Improvement of dose calculation accuracy for BNCT dosimetry by the multi-voxel method in JCDS
- Author
-
Kumada, H, Yamamoto, K, Yamamoto, T, Nakai, K, Nakagawa, Y, Kageji, T, and Matsumura, A
- Published
- 2004
- Full Text
- View/download PDF
14. Radiation injury of boron neutron capture therapy using mixed epithermal- and thermal neutron beams in patients with malignant glioma
- Author
-
Kageji, T, Nagahiro, S, Mizobuchi, Y, Toi, H, Nakagawa, Y, and Kumada, H
- Published
- 2004
- Full Text
- View/download PDF
15. Soft X-ray imaging using CR-39 plastics with AFM readout
- Author
-
Amemiya, K., Takahashi, H., Nakazawa, M., Shimizu, H., Majima, T., Nakagawa, Y., Yasuda, N., Yamamoto, M., Kageji, T., Nakaichi, M., Hasegawa, T., Kobayashi, T., Sakurai, Y., and Ogura, K.
- Published
- 2002
- Full Text
- View/download PDF
16. Ultra-high resolution radiography using CR-39 solid state track detectors and atomic force microscopy
- Author
-
Amemiya, K., Takahashi, H., Nakazawa, M., Yasuda, N., Yamamoto, M., Nakagawa, Y., Kageji, T., Nakaichi, M., and Ogura, K.
- Published
- 1999
- Full Text
- View/download PDF
17. CELL BIOLOGY AND SIGNALING
- Author
-
Agarwal, M., primary, Nitta, R., additional, Dovat, S., additional, Li, G., additional, Arita, H., additional, Narita, Y., additional, Fukushima, S., additional, Tateishi, K., additional, Matsushita, Y., additional, Yoshida, A., additional, Miyakita, Y., additional, Ohno, M., additional, Collins, V. P., additional, Kawahara, N., additional, Shibui, S., additional, Ichimura, K., additional, Kahn, S. A., additional, Gholamin, S., additional, Junier, M.-P., additional, Chneiweiss, H., additional, Weissman, I., additional, Mitra, S., additional, Cheshier, S., additional, Avril, T., additional, Hamlat, A., additional, Le Reste, P.-J., additional, Mosser, J., additional, Quillien, V., additional, Carrato, C., additional, Munoz-Marmol, A., additional, Serrano, L., additional, Pijuan, L., additional, Hostalot, C., additional, Villa, S. l., additional, Ariza, A., additional, Etxaniz, O., additional, Balana, C., additional, Benveniste, E. T., additional, Zheng, Y., additional, McFarland, B., additional, Drygin, D., additional, Bellis, S., additional, Bredel, M., additional, Lotsch, D., additional, Engelmaier, C., additional, Allerstorfer, S., additional, Grusch, M., additional, Pichler, J., additional, Weis, S., additional, Hainfellner, J., additional, Marosi, C., additional, Spiegl-Kreinecker, S., additional, Berger, W., additional, Bronisz, A., additional, Nowicki, M. O., additional, Wang, Y., additional, Ansari, K., additional, Chiocca, E. A., additional, Godlewski, J., additional, Brown, K., additional, Kwatra, M., additional, Bui, T., additional, Zhu, S., additional, Kozono, D., additional, Li, J., additional, Kushwaha, D., additional, Carter, B., additional, Chen, C., additional, Schulte, J., additional, Srikanth, M., additional, Das, S., additional, Zhang, J., additional, Lathia, J., additional, Yin, L., additional, Rich, J., additional, Olson, E., additional, Kessler, J., additional, Chenn, A., additional, Cherry, A., additional, Haas, B., additional, Lin, Y. H., additional, Ong, S.-E., additional, Stella, N., additional, Cifarelli, C. P., additional, Griffin, R. J., additional, Cong, D., additional, Zhu, W., additional, Shi, Y., additional, Clark, P., additional, Kuo, J., additional, Hu, S., additional, Sun, D., additional, Bookland, M., additional, Darbinian, N., additional, Dey, A., additional, Robitaille, M., additional, Remke, M., additional, Faury, D., additional, Maier, C., additional, Malhotra, A., additional, Jabado, N., additional, Taylor, M., additional, Angers, S., additional, Kenney, A., additional, Ren, X., additional, Zhou, H., additional, Schur, M., additional, Baweja, A., additional, Singh, M., additional, Erdreich-Epstein, A., additional, Fu, J., additional, Koul, D., additional, Yao, J., additional, Saito, N., additional, Zheng, S., additional, Verhaak, R., additional, Lu, Z., additional, Yung, W. K. A., additional, Gomez, G., additional, Volinia, S., additional, Croce, C., additional, Brennan, C., additional, Cavenee, W., additional, Furnari, F., additional, Lopez, S. G., additional, Qu, D., additional, Petritsch, C., additional, Gonzalez-Huarriz, M., additional, Aldave, G., additional, Ravi, D., additional, Rubio, A., additional, Diez-Valle, R., additional, Marigil, M., additional, Jauregi, P., additional, Vera, B., additional, Rocha, A. A. d. l., additional, Tejada-Solis, S., additional, Alonso, M. M., additional, Gopal, U., additional, Isaacs, J., additional, Gruber-Olipitz, M., additional, Dabral, S., additional, Ramkissoon, S., additional, Kung, A., additional, Pak, E., additional, Chung, J., additional, Theisen, M., additional, Sun, Y., additional, Monrose, V., additional, Franchetti, Y., additional, Shulman, D., additional, Redjal, N., additional, Tabak, B., additional, Beroukhim, R., additional, Zhao, J., additional, Buonamici, S., additional, Ligon, K., additional, Kelleher, J., additional, Segal, R., additional, Canton, D., additional, Diaz, P., additional, Scott, J., additional, Hara, K., additional, Kageji, T., additional, Mizobuchi, Y., additional, Kitazato, K., additional, Okazaki, T., additional, Fujihara, T., additional, Nakajima, K., additional, Mure, H., additional, Kuwayama, K., additional, Hara, T., additional, Nagahiro, S., additional, Hill, L., additional, Botfield, H., additional, Hossain-Ibrahim, K., additional, Logan, A., additional, Cruickshank, G., additional, Liu, Y., additional, Gilbert, M., additional, Kyprianou, N., additional, Rangnekar, V., additional, Horbinski, C., additional, Hu, Y., additional, Vo, C., additional, Li, Z., additional, Ke, C., additional, Ru, N., additional, Hess, K. R., additional, Linskey, M. E., additional, Zhou, Y.-a. H., additional, Hu, F., additional, Vinnakota, K., additional, Wolf, S., additional, Kettenmann, H., additional, Jackson, P. J., additional, Larson, J. D., additional, Beckmann, D. A., additional, Moriarity, B. S., additional, Largaespada, D. A., additional, Jalali, S., additional, Agnihotri, S., additional, Singh, S., additional, Burrell, K., additional, Croul, S., additional, Zadeh, G., additional, Kang, S.-H., additional, Yu, M. O., additional, Song, N.-H., additional, Park, K.-J., additional, Chi, S.-G., additional, Chung, Y.-G., additional, Kim, S. K., additional, Kim, J. W., additional, Kim, J. Y., additional, Kim, J. E., additional, Choi, S. H., additional, Kim, T. M., additional, Lee, S.-H., additional, Kim, S.-K., additional, Park, S.-H., additional, Kim, I. H., additional, Park, C.-K., additional, Jung, H.-W., additional, Koldobskiy, M., additional, Ahmed, I., additional, Ho, G., additional, Snowman, A., additional, Raabe, E., additional, Eberhart, C., additional, Snyder, S., additional, Gugel, I., additional, Bornemann, A., additional, Pantazis, G., additional, Mack, S., additional, Shih, D., additional, Sabha, N., additional, Tatagiba, M., additional, Krischek, B., additional, Schulte, A., additional, Liffers, K., additional, Kathagen, A., additional, Riethdorf, S., additional, Westphal, M., additional, Lamszus, K., additional, Lee, J. S., additional, Xiao, J., additional, Patel, P., additional, Schade, J., additional, Wang, J., additional, Deneen, B., additional, Song, H.-R., additional, Leiss, L., additional, Gjerde, C., additional, Saed, H., additional, Rahman, A., additional, Lellahi, M., additional, Enger, P. O., additional, Leung, R., additional, Gil, O., additional, Lei, L., additional, Canoll, P., additional, Sun, S., additional, Lee, D., additional, Ho, A. S. W., additional, Pu, J. K. S., additional, Zhang, X.-q., additional, Lee, N. P., additional, Dat, P. J. R., additional, Leung, G. K. K., additional, Loetsch, D., additional, Steiner, E., additional, Holzmann, K., additional, Pirker, C., additional, Hlavaty, J., additional, Petznek, H., additional, Hegedus, B., additional, Garay, T., additional, Mohr, T., additional, Sommergruber, W., additional, Lukiw, W. J., additional, Jones, B. M., additional, Zhao, Y., additional, Bhattacharjee, S., additional, Culicchia, F., additional, Magnus, N., additional, Garnier, D., additional, Meehan, B., additional, McGraw, S., additional, Hashemi, M., additional, Lee, T. H., additional, Milsom, C., additional, Gerges, N., additional, Trasler, J., additional, Pawlinski, R., additional, Mackman, N., additional, Rak, J., additional, Maherally, Z., additional, Thorne, A., additional, An, Q., additional, Barbu, E., additional, Fillmore, H., additional, Pilkington, G., additional, Tan, S. L., additional, Tan, S., additional, Choi, S., additional, Potts, C., additional, Ford, D. A., additional, Nahle, Z., additional, Kenney, A. M., additional, Matlaf, L., additional, Khan, S., additional, Zider, A., additional, Singer, E., additional, Cobbs, C., additional, Soroceanu, L., additional, McFarland, B. C., additional, Hong, S. W., additional, Rajbhandari, R., additional, Twitty, G. B., additional, Gray, G. K., additional, Yu, H., additional, Benveniste, E. N., additional, Nozell, S. E., additional, Minata, M., additional, Kim, S., additional, Mao, P., additional, Kaushal, J., additional, Nakano, I., additional, Mizowaki, T., additional, Sasayama, T., additional, Tanaka, K., additional, Mizukawa, K., additional, Nishihara, M., additional, Nakamizo, S., additional, Tanaka, H., additional, Kohta, M., additional, Hosoda, K., additional, Kohmura, E., additional, Moeckel, S., additional, Meyer, K., additional, Leukel, P., additional, Bogdahn, U., additional, Riehmenschneider, M. J., additional, Bosserhoff, A. K., additional, Spang, R., additional, Hau, P., additional, Mukasa, A., additional, Watanabe, A., additional, Ogiwara, H., additional, Aburatani, H., additional, Mukherjee, J., additional, Obha, S., additional, See, W., additional, Pieper, R., additional, Otsuka, R., additional, Kung, D., additional, Sinha, T., additional, Meares, G., additional, Nozell, S., additional, Ott, M., additional, Litzenburger, U., additional, Rauschenbach, K., additional, Bunse, L., additional, Pusch, S., additional, Ochs, K., additional, Sahm, F., additional, Opitz, C., additional, von Deimling, A., additional, Wick, W., additional, Platten, M., additional, Peruzzi, P., additional, Read, R., additional, Fenton, T., additional, Wykosky, J., additional, Vandenberg, S., additional, Babic, I., additional, Iwanami, A., additional, Yang, H., additional, Mischel, P., additional, Thomas, J., additional, Ronellenfitsch, M. W., additional, Thiepold, A. L., additional, Harter, P. N., additional, Mittelbronn, M., additional, Steinbach, J. P., additional, Rybakova, Y., additional, Kalen, A., additional, Sarsour, E., additional, Goswami, P., additional, Silber, J., additional, Harinath, G., additional, Aldaz, B., additional, Fabius, A. W. M., additional, Turcan, S., additional, Chan, T. A., additional, Huse, J. T., additional, Sonabend, A. M., additional, Bansal, M., additional, Guarnieri, P., additional, Soderquist, C., additional, Yun, J., additional, Kennedy, B., additional, Sisti, J., additional, Bruce, S., additional, Bruce, R., additional, Shakya, R., additional, Ludwig, T., additional, Rosenfeld, S., additional, Sims, P. A., additional, Bruce, J. N., additional, Califano, A., additional, Stockhausen, M.-T., additional, Kristoffersen, K., additional, Olsen, L. S., additional, Poulsen, H. S., additional, Stringer, B., additional, Day, B., additional, Barry, G., additional, Piper, M., additional, Jamieson, P., additional, Ensbey, K., additional, Bruce, Z., additional, Richards, L., additional, Boyd, A., additional, Sufit, A., additional, Burleson, T., additional, Le, J. P., additional, Keating, A. K., additional, Sundstrom, T., additional, Varughese, J. K., additional, Harter, P., additional, Prestegarden, L., additional, Petersen, K., additional, Azuaje, F., additional, Tepper, C., additional, Ingham, E., additional, Even, L., additional, Johnson, S., additional, Skaftnesmo, K. O., additional, Lund-Johansen, M., additional, Bjerkvig, R., additional, Ferrara, K., additional, Thorsen, F., additional, Takeshima, H., additional, Yamashita, S., additional, Yokogami, K., additional, Mizuguchi, S., additional, Nakamura, H., additional, Kuratsu, J., additional, Fukushima, T., additional, Morishita, K., additional, Tang, Y., additional, Vaka, D., additional, Chen, S., additional, Ponnuswami, A., additional, Cho, Y.-J., additional, Monje, M., additional, Nakamura, T., additional, Cahill, D., additional, Tiemann, K., additional, Hedman, H., additional, Niclou, S. P., additional, Timmer, M., additional, Tjiong, R., additional, Rohn, G., additional, Goldbrunner, R., additional, Stavrinou, P., additional, Perrech, M., additional, Tokita, M., additional, Mikheev, S., additional, Sellers, D., additional, Mikheev, A., additional, Kosai, Y., additional, Rostomily, R., additional, Tritschler, I., additional, Seystahl, K., additional, Schroeder, J. J., additional, Weller, M., additional, Wade, A., additional, Robinson, A. E., additional, Phillips, J. J., additional, Gong, Y., additional, Ma, Y., additional, Cheng, Z., additional, Thompson, R., additional, Fan, Q.-W., additional, Cheng, C., additional, Gustafson, W., additional, Charron, E., additional, Zipper, P., additional, Wong, R., additional, Chen, J., additional, Lau, J., additional, Knobbe-Thosen, C., additional, Jura, N., additional, Reifenberger, G., additional, Shokat, K., additional, Weiss, W., additional, Wu, S., additional, Hu, J., additional, Taylor, T., additional, Villa, G. R., additional, Mischel, P. S., additional, Gonias, S. L., additional, Yamashita, D., additional, Kondo, T., additional, Takahashi, H., additional, Inoue, A., additional, Kohno, S., additional, Harada, H., additional, Ohue, S., additional, Ohnishi, T., additional, Li, P., additional, Ng, J., additional, Yuelling, L., additional, Du, F., additional, Curran, T., additional, Yang, Z.-j., additional, Zhu, D., additional, Castellino, R. C., additional, Van Meir, E. G., additional, Begum, G., additional, Wang, Q., additional, Yang, S.-S., additional, Lin, S.-H., additional, and Kahle, K., additional
- Published
- 2013
- Full Text
- View/download PDF
18. EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY
- Author
-
Aaberg-Jessen, C., primary, Fogh, L., additional, Halle, B., additional, Jensen, V., additional, Brunner, N., additional, Kristensen, B. W., additional, Abe, T., additional, Momii, Y., additional, Watanabe, J., additional, Morisaki, I., additional, Natsume, A., additional, Wakabayashi, T., additional, Fujiki, M., additional, Aldaz, B., additional, Fabius, A. W. M., additional, Silber, J., additional, Harinath, G., additional, Chan, T. A., additional, Huse, J. T., additional, Anai, S., additional, Hide, T., additional, Nakamura, H., additional, Makino, K., additional, Yano, S., additional, Kuratsu, J.-i., additional, Balyasnikova, I. V., additional, Prasol, M. S., additional, Kanoija, D. K., additional, Aboody, K. S., additional, Lesniak, M. S., additional, Barone, T., additional, Burkhart, C., additional, Purmal, A., additional, Gudkov, A., additional, Gurova, K., additional, Plunkett, R., additional, Barton, K., additional, Misuraca, K., additional, Cordero, F., additional, Dobrikova, E., additional, Min, H., additional, Gromeier, M., additional, Kirsch, D., additional, Becher, O., additional, Pont, L. B., additional, Kloezeman, J., additional, van den Bent, M., additional, Kanaar, R., additional, Kremer, A., additional, Swagemakers, S., additional, French, P., additional, Dirven, C., additional, Lamfers, M., additional, Leenstra, S., additional, Balvers, R., additional, Kleijn, A., additional, Lawler, S., additional, Gong, X., additional, Andres, A., additional, Hanson, J., additional, Delashaw, J., additional, Bota, D., additional, Chen, C.-C., additional, Yao, N.-W., additional, Chuang, W.-J., additional, Chang, C., additional, Chen, P.-Y., additional, Huang, C.-Y., additional, Wei, K.-C., additional, Cheng, Y., additional, Dai, Q., additional, Morshed, R., additional, Han, Y., additional, Auffinger, B., additional, Wainwright, D., additional, Zhang, L., additional, Tobias, A., additional, Rincon, E., additional, Thaci, B., additional, Ahmed, A., additional, He, C., additional, Lesniak, M., additional, Choi, Y. A., additional, Pandya, H., additional, Gibo, D. M., additional, Fokt, I., additional, Priebe, W., additional, Debinski, W., additional, Chornenkyy, Y., additional, Agnihotri, S., additional, Buczkowicz, P., additional, Rakopoulos, P., additional, Morrison, A., additional, Barszczyk, M., additional, Hawkins, C., additional, Chung, S., additional, Decollogne, S., additional, Luk, P., additional, Shen, H., additional, Ha, W., additional, Day, B., additional, Stringer, B., additional, Hogg, P., additional, Dilda, P., additional, McDonald, K., additional, Moore, S., additional, Hayden-Gephart, M., additional, Bergen, J., additional, Su, Y., additional, Rayburn, H., additional, Edwards, M., additional, Scott, M., additional, Cochran, J., additional, Das, A., additional, Varma, A. K., additional, Wallace, G. C., additional, Dixon-Mah, Y. N., additional, Vandergrift, W. A., additional, Giglio, P., additional, Ray, S. K., additional, Patel, S. J., additional, Banik, N. L., additional, Dasgupta, T., additional, Olow, A., additional, Yang, X., additional, Mueller, S., additional, Prados, M., additional, James, C. D., additional, Haas-Kogan, D., additional, Dave, N. D., additional, Desai, P. B., additional, Gudelsky, G. A., additional, Chow, L. M. L., additional, LaSance, K., additional, Qi, X., additional, Driscoll, J., additional, Ebsworth, K., additional, Walters, M. J., additional, Ertl, L. S., additional, Wang, Y., additional, Berahovic, R. D., additional, McMahon, J., additional, Powers, J. P., additional, Jaen, J. C., additional, Schall, T. J., additional, Eroglu, Z., additional, Portnow, J., additional, Sacramento, A., additional, Garcia, E., additional, Raubitschek, A., additional, Synold, T., additional, Esaki, S., additional, Rabkin, S., additional, Martuza, R., additional, Wakimoto, H., additional, Ferluga, S., additional, Tome, C. L., additional, Forde, H. E., additional, Netland, I. A., additional, Sleire, L., additional, Skeie, B., additional, Enger, P. O., additional, Goplen, D., additional, Giladi, M., additional, Tichon, A., additional, Schneiderman, R., additional, Porat, Y., additional, Munster, M., additional, Dishon, M., additional, Weinberg, U., additional, Kirson, E., additional, Wasserman, Y., additional, Palti, Y., additional, Gramatzki, D., additional, Staudinger, M., additional, Frei, K., additional, Peipp, M., additional, Weller, M., additional, Grasso, C., additional, Liu, L., additional, Berlow, N., additional, Davis, L., additional, Fouladi, M., additional, Gajjar, A., additional, Huang, E., additional, Hulleman, E., additional, Hutt, M., additional, Keller, C., additional, Li, X.-N., additional, Meltzer, P., additional, Quezado, M., additional, Quist, M., additional, Raabe, E., additional, Spellman, P., additional, Truffaux, N., additional, van Vurden, D., additional, Wang, N., additional, Warren, K., additional, Pal, R., additional, Grill, J., additional, Monje, M., additional, Green, A. L., additional, Ramkissoon, S., additional, McCauley, D., additional, Jones, K., additional, Perry, J. A., additional, Ramkissoon, L., additional, Maire, C., additional, Shacham, S., additional, Ligon, K. L., additional, Kung, A. L., additional, Zielinska-Chomej, K., additional, Grozman, V., additional, Tu, J., additional, Viktorsson, K., additional, Lewensohn, R., additional, Gupta, S., additional, Mladek, A., additional, Bakken, K., additional, Carlson, B., additional, Boakye-Agyeman, F., additional, Kizilbash, S., additional, Schroeder, M., additional, Reid, J., additional, Sarkaria, J., additional, Hadaczek, P., additional, Ozawa, T., additional, Soroceanu, L., additional, Yoshida, Y., additional, Matlaf, L., additional, Singer, E., additional, Fiallos, E., additional, Cobbs, C. S., additional, Hashizume, R., additional, Tom, M., additional, Ihara, Y., additional, Santos, R., additional, Torre, J. D. L., additional, Lepe, E., additional, Waldman, T., additional, James, D., additional, Huang, X., additional, Yu-Jen, L., additional, Gupta, N., additional, Solomon, D., additional, Zhang, Z., additional, Hayashi, T., additional, Adachi, K., additional, Nagahisa, S., additional, Hasegawa, M., additional, Hirose, Y., additional, Gephart, M. H., additional, Su, Y. S., additional, Hingtgen, S., additional, Kasmieh, R., additional, Nesterenko, I., additional, Figueiredo, J.-L., additional, Dash, R., additional, Sarkar, D., additional, Fisher, P., additional, Shah, K., additional, Horne, E., additional, Diaz, P., additional, Stella, N., additional, Huang, C., additional, Yang, H., additional, Wei, K., additional, Huang, T., additional, Hlavaty, J., additional, Ostertag, D., additional, Espinoza, F. L., additional, Martin, B., additional, Petznek, H., additional, Rodriguez-Aguirre, M., additional, Ibanez, C., additional, Kasahara, N., additional, Gunzburg, W., additional, Gruber, H., additional, Pertschuk, D., additional, Jolly, D., additional, Robbins, J., additional, Hurwitz, B., additional, Yoo, J. Y., additional, Bolyard, C., additional, Yu, J.-G., additional, Wojton, J., additional, Zhang, J., additional, Bailey, Z., additional, Eaves, D., additional, Cripe, T., additional, Old, M., additional, Kaur, B., additional, Serwer, L., additional, Le Moan, N., additional, Ng, S., additional, Butowski, N., additional, Krtolica, A., additional, Cary, S. P. L., additional, Johns, T., additional, Greenall, S., additional, Donoghue, J., additional, Adams, T., additional, Karpel-Massler, G., additional, Westhoff, M.-A., additional, Kast, R. E., additional, Dwucet, A., additional, Wirtz, C. R., additional, Debatin, K.-M., additional, Halatsch, M.-E., additional, Merkur, N., additional, Kievit, F., additional, Stephen, Z., additional, Wang, K., additional, Kolstoe, D., additional, Ellenbogen, R., additional, Zhang, M., additional, Kitange, G., additional, Haefner, E., additional, Knubel, K., additional, Pernu, B. M., additional, Sufit, A., additional, Pierce, A. M., additional, Nelson, S. K., additional, Keating, A. K., additional, Jensen, S. S., additional, Lachowicz, J., additional, Demeule, M., additional, Regina, A., additional, Tripathy, S., additional, Curry, J.-C., additional, Nguyen, T., additional, Castaigne, J.-P., additional, Davis, T., additional, Davis, A., additional, Tanaka, K., additional, Keating, T., additional, Getz, J., additional, Kapp, G. T., additional, Romero, J. M., additional, Lee, S., additional, Ramisetti, S., additional, Slagle-Webb, B., additional, Sharma, A., additional, Connor, J., additional, Lee, W.-S., additional, Kluk, M., additional, Aster, J. C., additional, Ligon, K., additional, Sun, S., additional, Lee, D., additional, Ho, A. S. W., additional, Pu, J. K. S., additional, Zhang, Z.-q., additional, Lee, N. P., additional, Day, P. J. R., additional, Leung, G. K. K., additional, Liu, Z., additional, Liu, X., additional, Madhankumar, A. B., additional, Miller, P., additional, Webb, B., additional, Connor, J. R., additional, Yang, Q. X., additional, Lobo, M., additional, Green, S., additional, Schabel, M., additional, Gillespie, Y., additional, Woltjer, R., additional, Pike, M., additional, Lu, Y.-J., additional, Luchman, H. A., additional, Stechishin, O., additional, Nguyen, S., additional, Cairncross, J. G., additional, Weiss, S., additional, Lun, X., additional, Wells, J. C., additional, Hao, X., additional, Grinshtein, N., additional, Kaplan, D., additional, Luchman, A., additional, Senger, D., additional, Robbins, S., additional, Madhankumar, A., additional, Rizk, E., additional, Payne, R., additional, Park, A., additional, Pang, M., additional, Harbaugh, K., additional, Wilisch-Neumann, A., additional, Pachow, D., additional, Kirches, E., additional, Mawrin, C., additional, McDonell, S., additional, Liang, J., additional, Piao, Y., additional, Nguyen, N., additional, Yung, A., additional, Verhaak, R., additional, Sulman, E., additional, Stephan, C., additional, Lang, F., additional, de Groot, J., additional, Mizobuchi, Y., additional, Okazaki, T., additional, Kageji, T., additional, Kuwayama, K., additional, Kitazato, K. T., additional, Mure, H., additional, Hara, K., additional, Morigaki, R., additional, Matsuzaki, K., additional, Nakajima, K., additional, Nagahiro, S., additional, Kumala, S., additional, Heravi, M., additional, Devic, S., additional, Muanza, T., additional, Knubel, K. H., additional, Neuwelt, A., additional, Wu, Y. J., additional, Donson, A., additional, Vibhakar, R., additional, Venkatamaran, S., additional, Amani, V., additional, Neuwelt, E., additional, Rapkin, L., additional, Foreman, N., additional, Ibrahim, F., additional, New, P., additional, Cui, K., additional, Zhao, H., additional, Chow, D., additional, Stephen, W., additional, Nozue-Okada, K., additional, Nagane, M., additional, McDonald, K. L., additional, Ogawa, D., additional, Chiocca, E., additional, Godlewski, J., additional, Patel, A., additional, Pasupuleti, N., additional, Gorin, F., additional, Valenzuela, A., additional, Leon, L., additional, Carraway, K., additional, Ramachandran, C., additional, Nair, S., additional, Quirrin, K.-W., additional, Khatib, Z., additional, Escalon, E., additional, Melnick, S., additional, Phillips, A., additional, Boghaert, E., additional, Vaidya, K., additional, Ansell, P., additional, Shalinsky, D., additional, Zhang, Y., additional, Voorbach, M., additional, Mudd, S., additional, Holen, K., additional, Humerickhouse, R., additional, Reilly, E., additional, Parab, S., additional, Diago, O., additional, Ryken, T., additional, Agarwal, S., additional, Al-Keilani, M., additional, Alqudah, M., additional, Sibenaller, Z., additional, Assemolt, M., additional, Sai, K., additional, Li, W.-y., additional, Li, W.-p., additional, Chen, Z.-p., additional, Saito, R., additional, Sonoda, Y., additional, Kanamori, M., additional, Yamashita, Y., additional, Kumabe, T., additional, Tominaga, T., additional, Sarkar, G., additional, Curran, G., additional, Jenkins, R., additional, Scharnweber, R., additional, Kato, Y., additional, Lin, J., additional, Everson, R., additional, Soto, H., additional, Kruse, C., additional, Liau, L., additional, Prins, R., additional, Semenkow, S., additional, Chu, Q., additional, Eberhart, C., additional, Sengupta, R., additional, Marassa, J., additional, Piwnica-Worms, D., additional, Rubin, J., additional, Shai, R., additional, Pismenyuk, T., additional, Moshe, I., additional, Fisher, T., additional, Freedman, S., additional, Simon, A., additional, Amariglio, N., additional, Rechavi, G., additional, Toren, A., additional, Yalon, M., additional, Shimazu, Y., additional, Kurozumi, K., additional, Ichikawa, T., additional, Fujii, K., additional, Onishi, M., additional, Ishida, J., additional, Oka, T., additional, Watanabe, M., additional, Nasu, Y., additional, Kumon, H., additional, Date, I., additional, Sirianni, R. W., additional, McCall, R. L., additional, Spoor, J., additional, van der Kaaij, M., additional, Geurtjens, M., additional, Veiseh, O., additional, Fang, C., additional, Leung, M., additional, Strohbehn, G., additional, Atsina, K.-K., additional, Patel, T., additional, Piepmeier, J., additional, Zhou, J., additional, Saltzman, W. M., additional, Takahashi, M., additional, Valdes, G., additional, Inagaki, A., additional, Kamijima, S., additional, Hiraoka, K., additional, Micewicz, E., additional, McBride, W. H., additional, Iwamoto, K. S., additional, Gruber, H. E., additional, Robbins, J. M., additional, Jolly, D. J., additional, McCully, C., additional, Bacher, J., additional, Thomas, T., additional, Murphy, R., additional, Steffen-Smith, E., additional, McAllister, R., additional, Pastakia, D., additional, Widemann, B., additional, Chen, P., additional, Hua, M., additional, Liu, H., additional, Woolf, E. C., additional, Abdelwahab, M. G., additional, Fenton, K. E., additional, Liu, Q., additional, Turner, G., additional, Preul, M. C., additional, Scheck, A. C., additional, Shen, W., additional, Brown, D., additional, Pedersen, H., additional, Hariono, S., additional, Yao, T.-W., additional, Sidhu, A., additional, Weiss, W. A., additional, Nicolaides, T. P., additional, and Olusanya, T., additional
- Published
- 2013
- Full Text
- View/download PDF
19. Akt2 and Akt3 play a pivotal role in malignant gliomas
- Author
-
Mure, H., primary, Matsuzaki, K., additional, Kitazato, K. T., additional, Mizobuchi, Y., additional, Kuwayama, K., additional, Kageji, T., additional, and Nagahiro, S., additional
- Published
- 2009
- Full Text
- View/download PDF
20. Pleomorphic xanthoastrocytoma: a comparative pathological study between conventional and anaplastic types
- Author
-
Hirose, T, primary, Ishizawa, K, additional, Sugiyama, K, additional, Kageji, T, additional, Ueki, K, additional, and Kannuki, S, additional
- Published
- 2007
- Full Text
- View/download PDF
21. Multiple cystic cavernous angiomas associated with hemorrhage
- Author
-
Yagi, K., primary, Kageji, T., additional, Nagahiro, S., additional, and Murayama, Y., additional
- Published
- 2004
- Full Text
- View/download PDF
22. Verification of the computational dosimetry system in JAERI (JCDS) for boron neutron capture therapy
- Author
-
Kumada, H, primary, Yamamoto, K, additional, Matsumura, A, additional, Yamamoto, T, additional, Nakagawa, Y, additional, Nakai, K, additional, and Kageji, T, additional
- Published
- 2004
- Full Text
- View/download PDF
23. Reduction of endothelial tight junction proteins is related to cerebral aneurysm formation in rats.
- Author
-
Tada Y, Yagi K, Kitazato KT, Tamura T, Kinouchi T, Shimada K, Matsushita N, Nakajima N, Satomi J, Kageji T, and Nagahiro S
- Published
- 2010
- Full Text
- View/download PDF
24. Optimal timing of neutron irradiation for boron neutron capture therapy after intravenous infusion of sodium borocaptate in patients with glioblastoma
- Author
-
Kageji, T., Nagahiro, S., Kitamura, K., Nakagawa, Y., Hatanaka, H., Haritz, D., Grochulla, F., Haselsberger, K., and Gabel, D.
- Published
- 2001
- Full Text
- View/download PDF
25. <atl>Soft X-ray imaging using CR-39 plastics with AFM readout
- Author
-
Amemiya, K., Takahashi, H., Nakazawa, M., Shimizu, H., Majima, T., Nakagawa, Y., Yasuda, N., Yamamoto, M., Kageji, T., Nakaichi, M., Hasegawa, T., Kobayashi, T., Sakurai, Y., and Ogura, K.
- Subjects
- *
X-ray microscopy , *ATOMIC force microscopy , *NUCLEAR track detectors , *IMAGING systems in biology - Abstract
Soft X-ray microscopy using CR-39 plastic track detectors was demonstrated with an atomic force microscope (AFM) readout for the first time. A transmission X-ray image of the biological cells was recorded on the CR-39 surface, and revealed as relief after etching process. The resolution of the X-ray imaging is expected to be 100 nm or less, therefore imaging of biological cells is possible at an intracellular structure level. Using this technique, the high resolution image of both biological cells and charged particle tracks can be obtained simultaneously on a CR-39 with the AFM. In boron neutron capture therapy, this new technique provides the information on the distribution of boron compounds and radiation dose by charged particles mapping inside a cell. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
26. The Respiratory Adjusted Shock Index at Admission Is a Valuable Predictor of In-Hospital Outcomes for Elderly Emergency Patients with Medical Diseases at a Japanese Community General Hospital.
- Author
-
Hori T, Aihara KI, Watanabe T, Inaba K, Inaba K, Kaneko Y, Kawata S, Kawahito K, Kita H, Shimizu K, Hosoki M, Mori K, Kageji T, Uraoka H, and Nakamura S
- Abstract
Background : The respiratory adjusted shock index (RASI) is a risk score whose usefulness in patients with sepsis and trauma has previously been reported. However, its relevance in elderly emergency patients with medical diseases is yet to be clarified. This study assessed the usefulness of the RASI, which can be evaluated without requiring special equipment, to provide objective and rapid emergency responses. Methods : In this retrospective study, we recruited patients with medical diseases, aged 65 years or older, who were transported to the emergency room from Tokushima Prefectural Kaifu Hospital and underwent arterial blood gas testing from 1 January 2022 to 31 December 2023. We investigated the association of the RASI with other indices, including the lactate level, National Early Warning Score 2 (NEWS2), Shock Index (SI), Sequential Organ Failure Assessment (SOFA) score, quick SOFA (qSOFA) score, and systemic inflammatory response syndrome (SIRS). Results: In this study, we included 260 patients (mean age, 86 years), of whom 234 were admitted to the hospital; 27 and 49 patients died within 7 and 30 days of admission, respectively. The RASI was positively correlated with the lactate level, NEWS2, SI, and increase in the SOFA score ( p < 0.001). The RASI was higher in patients with a SIRS or qSOFA score ≥ 2 than in those without ( p < 0.001). It predicted death within 7 and 30 days of admission with an area under the curve (AUC) of 0.80 (95% confidence interval [CI]: 0.73-0.87), sensitivity of 96.3%, and specificity of 53.6% when the cutoff value was set to 1.58 and with an AUC of 0.73 (95% CI: 0.66-0.81), sensitivity of 69.4%, and specificity of 70.6% when the cutoff value was set to 1.83, respectively. Conclusions : The RASI is a simple indicator that can be used for predicting in-hospital outcomes in elderly emergency patients with medical diseases. Larger prospective studies based on this study are needed.
- Published
- 2024
- Full Text
- View/download PDF
27. Usefulness of Palliative Prognostic Index, Objective Prognostic Score, and Neutrophil-Lymphocyte Ratio/Albumin Ratio As Prognostic Indicators for Patients Without Cancer Receiving Home-Visit Palliative Care: A Pilot Study at a Community General Hospital.
- Author
-
Hori T, Aihara KI, Ishida K, Inaba K, Inaba K, Kaneko Y, Kawahito K, Bekku S, Hosoki M, Mori K, Itami K, Katsuse M, Hanaoka Y, Kageji T, Uraoka H, and Nakamura S
- Abstract
Background: Although the palliative prognostic index (PPI), objective prognostic score (OPS), and neutrophil-lymphocyte ratio/albumin ratio (NLR/Alb) are well-known prognostic indicators for cancer patients, they do not provide clarity when it comes to predicting prognosis in patients without cancer who receive home-visit palliative care., Objective: The aim of this study was to determine whether PPI, OPS, and NLR/Alb can predict prognosis for patients without cancer who received home-visit palliative care., Design: This is a retrospective study., Setting/subjects: We recruited 58 patients without cancer who received home-visit palliative care from Tokushima Prefectural Kaifu Hospital, Japan, and died at home or at the hospital within seven days of admission between January 2009 and March 2023., Measurements: The PPI, OPS, and NLR/Alb of the study patients were evaluated at regular intervals, and statistical analysis was performed on the relationship between these indices and the time to death., Results: Simple regression analysis showed that PPI, OPS, and NLR/Alb were negatively correlated with the period until death ( p < 0.001). The survival curves of the groups classified according to PPI, OPS, and NLR/Alb were significantly stratified. The predictive capacities of PPI, OPS, and NLR/Alb for death within 21 days were as follows: PPI (area under the curve [AUC]: 0.71; sensitivity: 59%; specificity: 68%), OPS (AUC: 0.73; sensitivity: 88%; specificity: 47%), and NLR/Alb (AUC: 0.72; sensitivity: 72%; specificity: 73%)., Conclusions: PPI, OPS, and NLR/Alb were useful in predicting the survival period and short-term prognosis within 21 days for patients without cancer who received home-visit palliative care., Competing Interests: No competing financial interests exist., (© Taiki Hori et al., 2024; Published by Mary Ann Liebert, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
28. Diagnostic Performance of Arterial Spin Labeling for Grading Nonenhancing Astrocytic Tumors.
- Author
-
Khashbat D, Harada M, Abe T, Ganbold M, Iwamoto S, Uyama N, Irahara S, Otomi Y, Kageji T, and Nagahiro S
- Subjects
- Cerebrovascular Circulation physiology, Humans, Spin Labels, Astrocytoma blood supply, Astrocytoma diagnostic imaging, Brain Neoplasms blood supply, Brain Neoplasms diagnostic imaging, Magnetic Resonance Angiography methods
- Abstract
Purpose: We evaluated the utility of arterial spin labeling (ASL) imaging of tumor blood flow (TBF) for grading non-enhancing astrocytic tumors., Materials and Methods: Thirteen non-enhancing astrocytomas were divided into high-grade (n = 7) and low-grade (n = 6) groups. Both ASL and conventional sequences were acquired using the same magnetic resonance machine. Intratumoral absolute maximum TBF (TBF
max ), absolute mean TBF (TBFmean ), and corresponding values normalized to cerebral blood flow (TBFmax and TBFmean ratios) were measured. The Mann-Whitney U test and receiver operating characteristic (ROC) curve analysis were used to assess the accuracy of TBF variables for tumor grading., Results: Compared with low-grade astrocytoma, high-grade astrocytoma exhibited significantly greater absolute TBFmax (90.93 ± 24.96 vs 46.94 ± 20.97 ml/100 g/min, P < 0.001), TBFmean (58.75 ± 19.89 vs 31.16 ± 17.63 ml/100 g/min, P < 0.001), TBFmax ratio (3.34 ± 1.22 vs 1.35 ± 0.5, P < 0.001), and TBFmean ratio (2.15 ± 0.94 vs 0.88 ± 0.41, P < 0.001). The TBFmax ratio yielded the highest diagnostic accuracy (sensitivity 100%, specificity 86.3%), while absolute TBFmean yielded the lowest accuracy (sensitivity 85.7%, specificity 70.1%) by ROC analysis., Conclusion: Parameters from ASL perfusion imaging, particularly TBFmax ratio, may be useful for distinguishing high-grade from low-grade astrocytoma in cases with equivocal conventional MRI findings.- Published
- 2018
- Full Text
- View/download PDF
29. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model.
- Author
-
Fujihara T, Mizobuchi Y, Nakajima K, Kageji T, Matsuzaki K, Kitazato KT, Otsuka R, Hara K, Mure H, Okazaki T, Kuwayama K, Nagahiro S, and Takagi Y
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Animals, Brain Neoplasms pathology, Cell Line, Tumor, Down-Regulation drug effects, Gene Expression Regulation, Neoplastic drug effects, Glioblastoma pathology, Humans, Intercellular Signaling Peptides and Proteins metabolism, Male, Mice, Inbred BALB C, NF-kappa B metabolism, Proto-Oncogene Proteins c-akt metabolism, Random Allocation, Signal Transduction drug effects, Xenograft Model Antitumor Assays, Antineoplastic Agents, Alkylating pharmacology, Brain Neoplasms drug therapy, Brain Neoplasms metabolism, Glioblastoma drug therapy, Glioblastoma metabolism, Temozolomide pharmacology
- Abstract
Background: Glioblastoma multiforme (GBM) is the most malignant of brain tumors. Acquired drug resistance is a major obstacle for successful treatment. Earlier studies reported that expression of the multiple drug resistance gene (MDR1) is regulated by YB-1 or NFκB via the JNK/c-Jun or Akt pathway. Over-expression of the Dickkopf (DKK) family member DKK3 by an adenovirus vector carrying DKK3 (Ad-DKK3) exerted anti-tumor effects and led to the activation of the JNK/c-Jun pathway. We investigated whether Ad-DKK3 augments the anti-tumor effect of temozolomide (TMZ) via the regulation of MDR1., Methods: GBM cells (U87MG and U251MG), primary TGB105 cells, and mice xenografted with U87MG cells were treated with Ad-DKK3 or TMZ alone or in combination., Results: Ad-DKK3 augmentation of the anti-tumor effects of TMZ was associated with reduced MDR1 expression in both in vivo and in vitro studies. The survival of Ad-DKK3-treated U87MG cells was inhibited and the expression of MDR1 was reduced. This was associated with the inhibition of Akt/NFκB but not of YB-1 via the JNK/c-Jun- or Akt pathway., Conclusions: Our results suggest that Ad-DKK3 regulates the expression of MDR1 via Akt/NFκB pathways and that it augments the anti-tumor effects of TMZ in GBM cells.
- Published
- 2018
- Full Text
- View/download PDF
30. Design and Synthesis of Novel Anti-metastatic Hypoxic Cytotoxin TX-2137 Targeting AKT Kinase.
- Author
-
Shiba I, Kouzaki R, Yamada H, Endo Y, Takino T, Sato H, Kitazato K, Kageji T, Nagahiro S, and Uto Y
- Subjects
- A549 Cells, Animals, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Cell Hypoxia drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Chick Embryo, Drug Design, Humans, Liver Neoplasms secondary, Matrix Metalloproteinase 9 metabolism, Mice, Neoplasm Metastasis, Phosphorylation drug effects, Protein Kinase Inhibitors chemistry, Protein Kinase Inhibitors pharmacology, Xenograft Model Antitumor Assays, Antineoplastic Agents administration & dosage, Antineoplastic Agents chemical synthesis, Liver Neoplasms drug therapy, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors chemical synthesis, Proto-Oncogene Proteins c-akt antagonists & inhibitors
- Abstract
Background: The hypoxic microenvironment plays a crucial role in the malignant progression of tumor cells. Moreover, AKT, a serine/threonine kinase, is activated by various extracellular growth factors and is important for cell growth, survival, and motility of leukocytes, fibroblasts, endothelial cells, and tumor cells. Therefore, we aimed to design an anti-metastatic hypoxic cytotoxin which has inhibitory effects on AKT., Results: TX-2137 was designed and synthesized based on the structural similarity of a preexisting AKT1/2 kinase inhibitor and a hypoxic cytotoxin tirapazamine. TX-2137 effectively reduced the expression of phosphorylated AKT and matrix metalloproteinase 9 (MMP9) and showed strong inhibition of the proliferation of B16-F10, HT-1080, and MKN-45 cells. In addition, TX-2137 exhibited hypoxia-selective cytotoxicity towards A549 cells and inhibited liver metastasis of B16-F10 cells in a xenograft chick embryo model in the same way as doxorubicin., Conclusion: TX-2137 may be a potent lead compound in the development of a novel anti-metastatic AKT kinase inhibitor., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
31. Postoperative Hematoma Requiring Recraniotomy in 1149 Consecutive Patients With Intracranial Tumors.
- Author
-
Kageji T, Nagahiro S, Mizobuchi Y, and Nakajima K
- Subjects
- Adolescent, Adult, Age Distribution, Aged, Aged, 80 and over, Brain Neoplasms mortality, Child, Child, Preschool, Female, Hematoma surgery, Humans, Infant, Infant, Newborn, Male, Middle Aged, Reoperation methods, Retrospective Studies, Risk Factors, Young Adult, Brain Neoplasms surgery, Craniotomy adverse effects, Hematoma epidemiology, Hematoma etiology, Postoperative Complications epidemiology, Postoperative Complications etiology
- Abstract
Background: The reported 30-day mortality rate after brain tumor surgery is 2.2% to 2.9%, with a postoperative hematoma (POH) as the most frequent cause of death., Objective: To investigate the risk factors for a POH requiring a recraniotomy after brain tumor surgery in a large, contemporary, single-institution consecutive series., Methods: We included 1149 patients who underwent surgery for intracranial tumors at the Tokushima University Hospital from 1997 to 2014. The patient charts were retrospectively studied from our prospectively collected database. We analyzed the risk factors, type of hemorrhage, time to reoperation, and outcomes., Results: The incidence of a POH requiring a recraniotomy was 2.09%. Among the patients with a POH requiring a recraniotomy, 12.5% died within 30 days of the first surgery. The incidence of a POH requiring a recraniotomy significantly correlated with the incidence of a hemangioblastoma, infratentorial tumors, and a prolonged operative time (>10 h), but not with the patient age or sex, surgical procedure (biopsy or craniotomy), surgical type (primary or secondary), bleeding volume, or intraoperative blood transfusion requirement. A recraniotomy for a POH was performed in 54% of the patients just after the first operation, and within 24 h for 79% of the patients. The clinical status at the time of discharge deteriorated in 52% of the patients., Conclusion: Hemangioblastomas, infratentorial tumors, and an operative time exceeding 10 h were significantly correlated with an increased risk of a POH; these factors were responsible for 12.5% of the 30-day surgical mortality rate., (Copyright © 2017 by the Congress of Neurological Surgeons)
- Published
- 2017
- Full Text
- View/download PDF
32. Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma.
- Author
-
Sato A, Mizobuchi Y, Nakajima K, Shono K, Fujihara T, Kageji T, Kitazato K, Matsuzaki K, Mure H, Kuwayama K, Sumi A, Saya H, Sampetrean O, and Nagahirao S
- Subjects
- Animals, Apoptosis drug effects, Brain metabolism, Celecoxib pharmacology, Cell Line, Tumor, Cell Proliferation drug effects, Cyclooxygenase 2 Inhibitors pharmacology, Enzyme Inhibitors pharmacology, Female, Gene Expression Regulation, Neoplastic physiology, Gene Expression Regulation, Neoplastic radiation effects, Humans, Inhibitor of Apoptosis Proteins metabolism, Inhibitor of Apoptosis Proteins pharmacology, Inhibitor of Differentiation Proteins metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Neoplasm Proteins metabolism, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction drug effects, Survivin, Apoptosis physiology, Brain pathology, Brain Neoplasms pathology, Cell Proliferation physiology, Cyclooxygenase 2 metabolism, Glioma pathology, Signal Transduction physiology
- Abstract
Approximately half of surgically-treated patients with low-grade-glioma (LGG) suffer recurrence or metastasis. Currently there is no effective drug treatment. While the selective COX-2 inhibitor celecoxib showed anti-neoplastic activity against several malignant tumors, its effects against LGG remain to be elucidated. Ours is the first report that the expression level of COX-2 in brain tissue samples from patients with LGG and in LGG cell lines is higher than in the non-neoplastic region and in normal brain cells. We found that celecoxib attenuated LGG cell proliferation in a dose-dependent manner. It inhibited the generation of prostaglandin E2 and induced apoptosis and cell-cycle arrest. We also show that celecoxib hampered the activation of the Akt/survivin- and the Akt/ID3 pathway in LGGs. These findings suggest that celecoxib may have a promising therapeutic potential and that the early treatment of LGG patients with the drug may be beneficial.
- Published
- 2017
- Full Text
- View/download PDF
33. Congenital craniopharyngioma treated by radical surgery: case report and review of the literature.
- Author
-
Kageji T, Miyamoto T, Kotani Y, Kaji T, Bando Y, Mizobuchi Y, Nakajima K, and Nagahiro S
- Subjects
- Craniopharyngioma diagnostic imaging, Female, Humans, Magnetic Resonance Imaging, Pituitary Neoplasms diagnostic imaging, Pregnancy, Tomography, X-Ray Computed, Ultrasonography, Prenatal, Craniopharyngioma surgery, Neurosurgical Procedures methods, Pituitary Neoplasms surgery
- Abstract
Purpose: Craniopharyngiomas are 5-10 % of all pediatric tumors, but are seldomly encountered in the perinatal period. Only seven instances of a truly antenatal diagnosis of a congenital craniopharyngioma that subsequently underwent radical surgery have been reported. We present the case of a patient who received the diagnosis of a suprasellar tumor during the prenatal period and received radical surgery., Methods: We report a case of a neonatal craniopharyngioma treated surgically., Results: The pregnancy progressed uneventfully until a routine ultrasound at 37 weeks of gestation showed a 15 × 15 mm high echoic mass in the center of the fetal head. Neonatal Gd-enhanced T1-weighted MRI at 5 days of life showed a homogenously enhanced mass (16×22×15 mm) in the sellar and suprasellar lesion. As the tumor showed rapid growth at the 3rd month of life, the patient underwent a surgical treatment and the mass was totally removed. Three years later, the physical and mental development of the patient was normal, and Gd-MRI studies showed no tumor recurrence., Conclusion: The present case is the eighth case of a truly antenatal diagnosis of a craniopharyngioma that underwent successful radical surgery. Craniopharyngioma is a benign tumor and thought to be a slow growing tumor in childhood. The results of radical surgery were very poor, and the mortality and morbidity rates were high in the previous reports due to the huge size of tumor at operation. The present case demonstrated the rapid growth in short interval of Gd-MRI. This is the first report of tumor kinetics of congenital craniopharyngioma with previous reports. The calculated tumor doubling time in our case was 37 days.
- Published
- 2017
- Full Text
- View/download PDF
34. Characteristics of medical students who would like to be a generalist physician and contribute to remote area medicine.
- Author
-
Tani K, Okura Y, Tabata R, Yuasa S, Kawaminami S, Nakanishi Y, Kawahito K, Inaba K, Inaba K, Kageji T, Tanaka H, Suzuki Y, and Yamaguchi H
- Subjects
- Adult, Community Health Services, Female, Humans, Male, Motivation, Surveys and Questionnaires, Career Choice, General Practitioners, Students, Medical
- Abstract
We administered a questionnaire to 5
th grade medical students to examine the effect of community-based clinical practice on their attitudes to remote area medicine and their course after the graduation. Data from 192 students were obtained. The intensity of students' attitudes was estimated by using visual analogue scale. The intensities of the interest and a sense of fulfillment in remote area medicine were significantly increased after the practice. A significantly lower level of the intensity to become a generalist than that to become a specialist was seen in the students with low intensity in a sense of fulfillment. The percentages of the students who answered that they can work for 5 years or more in remote area were significantly lower in students with low intensity of a sense of fulfillment than in those with high intensity. A significantly higher percentage in students who worked at a familiar prefecture to them after the graduation was seen in female than in male. This study shows that the community-based practice is meaningful in increasing motivation which desire to work in remote area medicine, and that the motivation may affect their course after the graduation. J. Med. Invest. 64: 210-216, August, 2017.- Published
- 2017
- Full Text
- View/download PDF
35. Differences In High-Intensity Signal Volume Between Arterial Spin Labeling And Contrast-Enhanced T1-Weighted Imaging May Be Useful For Differentiating Glioblastoma From Brain Metastasis.
- Author
-
Ganbold M, Harada M, Khashbat D, Abe T, Kageji T, and Nagahiro S
- Subjects
- Adult, Aged, Aged, 80 and over, Brain Neoplasms diagnosis, Diagnosis, Differential, Female, Glioblastoma diagnosis, Humans, Magnetic Resonance Angiography methods, Male, Middle Aged, Prospective Studies, Spin Labels, Brain Neoplasms diagnostic imaging, Brain Neoplasms secondary, Glioblastoma diagnostic imaging
- Abstract
Purpose: To determine whether differences in tumor volume between arterial spin labeling (ASL) and contrast-enhanced T1-weighted MR images (CE+T1WI) can help differentiate glioblastoma (GBM) from brain metastasis., Materials and Methods: Patients with a diagnosis of GBM (n=25) or brain metastasis (n=13) were examined by both conventional and ASL MR imaging. Volumes of interest with high signal intensity on ASL and CE+T1WI were defined using three dimensional analysis software. Tumor volume difference (ASL-CE) and tumor volume ratio (ASL/CE) were obtained. Absolute maximal tumor blood flow (TBF) and TBF ratio (normalized to white matter) were also measured. The Mann-Whitney U test and receiver operating characteristic curve analysis were performed to compare measurements between the tumor groups., Results: Both tumor volume difference and tumor volume ratio were significantly higher in GBM than in metastasis. Both TBF and TBF ratio were higher for GBM than for metastasis, but the differences were not significant., Conclusion: The difference in tumor volume as measured by ASL high signal intensity and CE+T1WI might be useful for differentiating GBM from metastasis, whereas ASL-derived TBF is insufficient. J. Med. Invest. 64: 58-63, February, 2017.
- Published
- 2017
- Full Text
- View/download PDF
36. Drip-and-Ship Thrombolytic Therapy Supported by the Telestroke System for Acute Ischemic Stroke Patients Living in Medically Under-served Areas.
- Author
-
Kageji T, Obata F, Oka H, Kanematsu Y, Tabata R, Tani K, Bando H, and Nagahiro S
- Subjects
- Aged, Aged, 80 and over, Female, Fibrinolytic Agents therapeutic use, Humans, Japan, Male, Time-to-Treatment, Tissue Plasminogen Activator therapeutic use, Treatment Outcome, Medically Underserved Area, Stroke diagnosis, Stroke therapy, Telemedicine, Thrombolytic Therapy
- Abstract
There are a few stroke specialists in medically under-served areas in Japan. Consequently, in remote area patients may not receive thrombolysis with intravenous recombinant tissue plasminogen activator (iv rt-PA), the standard treatment for acute ischemic stroke. Using a mobile telestroke support system (TSS) that accesses the internet via a smart phone, we implemented iv rt-PA infusion therapy under a drip-and-ship protocol to treat the stroke patients in medically under-served areas. The physicians at the Tokushima Prefectural Kaifu Hospital (TPKH), located in rural Japan, can relay CT or MRI scans and other patient data via their smart phone to off-site stroke specialists. In the course of 34 months, we used the TSS in 321 emergencies. A total of 9 of 188 (4.8%) with acute ischemic stroke, received iv rt-PA infusion therapy using a mobile TSS; in 5 among these (55.6%), we obtained partial or complete recanalization of occluded arteries. None suffered post-treatment hemorrhage and their average NIH stroke score fell from 14.6 at the time of admission to 6.8 at 24 h post-infusion. The drip-and-ship protocol contributed to the safe and effective treatment of the stroke patients living in medically under-served rural areas., Competing Interests: The authors have no personal financial or institutional interest in any of the drugs, materials, or devices cited in this study.
- Published
- 2016
- Full Text
- View/download PDF
37. Comparison of Brain Tumor Contrast-enhancement on T1-CUBE and 3D-SPGR Images.
- Author
-
Majigsuren M, Abe T, Kageji T, Matsuzaki K, Takeuchi M, Iwamoto S, Otomi Y, Uyama N, Nagahiro S, and Harada M
- Subjects
- Adult, Aged, Aged, 80 and over, Astrocytoma diagnosis, Brain Neoplasms secondary, Female, Gadolinium DTPA, Humans, Image Processing, Computer-Assisted methods, Lymphoma, Large B-Cell, Diffuse diagnosis, Male, Meningioma diagnosis, Middle Aged, Oligodendroglioma diagnosis, Signal-To-Noise Ratio, White Matter pathology, Brain Neoplasms diagnosis, Contrast Media, Image Enhancement methods, Imaging, Three-Dimensional methods, Magnetic Resonance Imaging methods
- Abstract
Purpose: T1-Cube (GE HealthCare) is a relatively new 3-dimensional (3D) fast spin-echo (FSE)-based magnetic resonance (MR) imaging sequence that uses a variable flip angle to acquire gap-free volume scans. We compared the gadolinium enhancement characteristics of a heterogeneous population of brain tumors imaged by T1-Cube and then 3D fast spoiled gradient recall acquisition in steady state (3D FSPGR) 3-tesla MR imaging to identify the superior modality for specific diagnostic purposes., Methods: We examined 61 lesions from 32 patients using the 2 sequences after administration of gadopentetic acid (Gd-DTPA; 0.1 mmol/kg). Two neuroradiologists independently measured each lesion twice using a region-of-interest (ROI) method. We measured the contrast-to-noise ratio (CNR), the difference in signal intensity (SI) between the tumor and normal white matter relative to the standard deviation (SD) of the SI within the lesion, for both post-contrast 3D FSPGR and post-contrast T1-Cube images of the same tumor and compared modality-specific CNRs for all tumors and in subgroups defined by tumor size, enhancement ratio, and histopathology., Results: The mean CNR was significantly higher on T1-Cube images than 3D FSPGR images for the total tumor population (1.85 ± 0.97 versus 1.12 ± 1.05, P < 0.01) and the histologic types, i.e., metastasis (P < 0.01) and lymphoma (P < 0.05). The difference in CNR was even larger for smaller tumors in the metastatic group (4.95 to 23.5 mm(2)) (P < 0.01). In contrast, mean CNRs did not differ between modalities for high grade glioma and meningioma., Conclusions: Gadolinium enhancement of brain tumors was generally higher when imaged by T1-Cube than 3D FSPGR, and T1-Cube with Gd enhancement may be superior to 3D FSPGR for detecting smaller metastatic tumors.
- Published
- 2016
- Full Text
- View/download PDF
38. Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan.
- Author
-
Tada Y, Yagi K, Uno M, Matsushita N, Kanematsu Y, Kuwayama K, Shimada K, Nishi K, Hirasawa M, Satomi J, Kitazato KT, Kageji T, Matsuura E, and Nagahiro S
- Subjects
- Aged, Angiotensin I blood, Angiotensin II Type 1 Receptor Blockers adverse effects, Antihypertensive Agents adverse effects, Blood Pressure drug effects, Female, Humans, Hypertension blood, Hypertension diagnosis, Hypertension physiopathology, Japan, Lipoproteins, LDL blood, Male, Middle Aged, Olmesartan Medoxomil adverse effects, Peptide Fragments blood, Peroxiredoxins blood, Prospective Studies, Stroke blood, Stroke diagnosis, Stroke physiopathology, Time Factors, Treatment Outcome, beta 2-Glycoprotein I blood, Angiotensin II Type 1 Receptor Blockers therapeutic use, Antihypertensive Agents therapeutic use, Biomarkers blood, Drug Substitution, Hypertension drug therapy, Olmesartan Medoxomil therapeutic use, Stroke drug therapy
- Abstract
Background: Managing hypertension is crucial for preventing stroke recurrence. Some stroke patients experience resistant hypertension. In our experimental stroke model, olmesartan increased the expression of angiotensin (Ang) II converting enzyme-2. We hypothesized that switching to olmesartan affects biomarkers and the blood pressure (BP) in stroke patients whose BP is insufficiently controlled by standard doses of Ang II type I receptor blockers (ARBs) other than olmesartan., Methods: We recruited 25 patients to study our hypothesis. All had a history of stroke or silent cerebral infarction. We switched them to olmesartan (10-40 mg per day) for 12 weeks and determined their plasma level of Ang-(1-7), peroxiredoxin, oxidized low-density lipoprotein (oxLDL)/β-2-glycoprotein I (β2GPI) complex, adiponectin, high mobility group box 1 (HMGB1), and tumor necrosis factor-α (TNFα) and recorded their BP before and after olmesartan treatment., Results: After switching the patients to olmesartan, their plasma level of Ang-(1-7) as a vasoprotective indicator and adiponectin regulating metabolic syndrome was increased, and peroxiredoxin and the oxLDL/β2GPI complex indicating its antioxidative stress and its proatherogenicity were lower than their baseline. This suggests that olmesartan may be more effective than other ARBs to improve these conditions. Neither HMGB1 nor TNFα reflecting an inflammatory response was affected, suggesting that the anti-inflammatory effects of olmesartan are similar to those of other ARBs. The recommended BP (<140/90) was obtained in 10 of the 25 patients after switching to olmesartan. No adverse events occurred., Conclusions: Switching from other ARBs to olmesartan may be a promising therapeutic option in patients with resistant hypertension., (Copyright © 2015 National Stroke Association. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
39. Diagnosis of brain tumors using dynamic contrast-enhanced perfusion imaging with a short acquisition time.
- Author
-
Abe T, Mizobuchi Y, Nakajima K, Otomi Y, Irahara S, Obama Y, Majigsuren M, Khashbat D, Kageji T, Nagahiro S, and Harada M
- Abstract
This study sought to determine the diagnostic utility of perfusion parameters derived from dynamic contrast-enhanced (DCE) perfusion MRI with a short acquisition time (approximately 3.5 min) in patients with glioma, brain metastasis, and primary CNS lymphoma (PCNSL). Twenty-six patients with 29 lesions (4 low-grade glioma, 13 high-grade glioma, 7 metastasis, and 5 PCNSL) underwent DCE-MRI in a 3 T scanner. A ROI was placed on the hotspot of each tumor in maps for volume transfer contrast K (trans) , extravascular extracellular volume V e , and fractional plasma volume V p . We analyzed differences in parameters between tumors using the Mann-Whitney U test. We calculated sensitivity and specificity using receiver operating characteristics analysis. Mean K (trans) values of LGG, HGG, metastasis and PCNSL were 0.034, 0.31, 0.38, 0.44, respectively. Mean Ve values of each tumors was 0.036, 0.57, 0.47, 0.96, and mean Vp value of each tumors was 0.070, 0.086, 0.26, 0.17, respectively. Compared with other tumor types, low-grade glioma showed lower K (trans) (P < 0.01, sensitivity = 88%, specificity = 100%) and lower V e (P < 0.01, sensitivity = 96%, specificity = 100%). PCNSL showed higher V e (P < 0.01, sensitivity = 100%, specificity = 88%), but the other perfusion parameters overlapped with those of different histology. Kinetic parameters derived from DCE-MRI with short acquisition time provide useful information for the differential diagnosis of brain tumors.
- Published
- 2015
- Full Text
- View/download PDF
40. Blocking of the interaction between Wnt proteins and their co-receptors contributes to the anti-tumor effects of adenovirus-mediated DKK3 in glioblastoma.
- Author
-
Hara K, Kageji T, Mizobuchi Y, Kitazato KT, Okazaki T, Fujihara T, Nakajima K, Mure H, Kuwayama K, Hara T, and Nagahiro S
- Subjects
- Adaptor Proteins, Signal Transducing, Animals, Apoptosis, Blotting, Western, Cell Proliferation, Chemokines, Flow Cytometry, Genetic Vectors administration & dosage, Glioblastoma metabolism, Glioblastoma pathology, Humans, Immunoenzyme Techniques, Immunoprecipitation, Intercellular Signaling Peptides and Proteins genetics, Low Density Lipoprotein Receptor-Related Protein-6 genetics, Low Density Lipoprotein Receptor-Related Protein-6 metabolism, Male, Mice, Mice, Inbred BALB C, Mice, Nude, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Receptor Tyrosine Kinase-like Orphan Receptors genetics, Receptor Tyrosine Kinase-like Orphan Receptors metabolism, Reverse Transcriptase Polymerase Chain Reaction, Tumor Cells, Cultured, Wnt Proteins genetics, Wnt Proteins metabolism, Wnt-5a Protein, Wnt3A Protein genetics, Wnt3A Protein metabolism, Xenograft Model Antitumor Assays, Adenoviridae genetics, Glioblastoma prevention & control, Intercellular Signaling Peptides and Proteins metabolism, Low Density Lipoprotein Receptor-Related Protein-6 antagonists & inhibitors, Proto-Oncogene Proteins antagonists & inhibitors, Receptor Tyrosine Kinase-like Orphan Receptors antagonists & inhibitors, Wnt Proteins antagonists & inhibitors, Wnt3A Protein antagonists & inhibitors
- Abstract
The effect of the third member of the Dickkopf family (DKK3) in the Wnt pathway in glioblastoma remains unclear. We first demonstrated the non-specific interaction of Wnt3a and Wnt5a with the receptors LRP6 and ROR2 and the up-regulation of the Wnt pathway in glioblastoma cells. We used an adenovirus vector and found that an increase in DKK3 protein attenuated the expression of Wnt3a, Wnt5a and LRP6, but not of ROR2, and their interaction, thereby affecting both canonical- and non-canonical Wnt downstream cascades. This produced anti-tumor effects in GBM xenograft models. The suppression of Wnt pathways upstream by DKK3 may have promise for the treatment of glioblastoma., (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
41. Clinical Significance of Discrepancy between Arterial Spin Labeling Images and Contrast-enhanced Images in the Diagnosis of Brain Tumors.
- Author
-
Abe T, Mizobuchi Y, Sako W, Irahara S, Otomi Y, Obama Y, Nakajima K, Khashbat D, Majigsuren M, Kageji T, Nagahiro S, and Harada M
- Subjects
- Adult, Aged, Aged, 80 and over, Astrocytoma diagnosis, Astrocytoma pathology, Brain Neoplasms pathology, Brain Neoplasms secondary, Contrast Media, Diagnosis, Differential, Electron Spin Resonance Spectroscopy methods, Female, Follow-Up Studies, Gadolinium DTPA, Glioblastoma diagnosis, Glioblastoma pathology, Glioma pathology, Gliosarcoma diagnosis, Gliosarcoma pathology, Humans, Image Processing, Computer-Assisted methods, Lymphoma, Large B-Cell, Diffuse diagnosis, Lymphoma, Large B-Cell, Diffuse pathology, Magnetic Resonance Spectroscopy methods, Male, Middle Aged, Neoplasms, Neuroepithelial diagnosis, Neoplasms, Neuroepithelial pathology, Oligodendroglioma diagnosis, Oligodendroglioma pathology, Spin Labels, Brain Neoplasms diagnosis, Glioma diagnosis, Image Enhancement methods, Magnetic Resonance Imaging methods, Neuroimaging methods
- Abstract
Purpose: In the imaging of intra-axial brain tumors, we sometimes found areas of high signal intensity around the enhanced tumor lesions on arterial spin labeling (ASL) magnetic resonance (MR) imaging. We undertook this study to investigate the relationship between high signal intensity on ASL imaging outside the area of contrast enhancement (CE) and histological diagnosis of intra-axial brain tumors., Methods: We examined images from 28 consecutive patients with intra-axial brain tumors who underwent ASL and CE MR imaging-three with low grade glioma (LGG), 13 with high grade glioma (HGG), six with metastasis, and six with primary central nervous system lymphoma (PCNSL)-and divided imaging findings into an "ASL dominant" group when hyperintensity on ASL was found outside the CE area and a "CE dominant" group when hyperintensity on ASL was not found outside the area of enhancement. We then analyzed the relationship between imaging findings and the histological diagnosis of the tumors., Results: Four cases were excluded because of poor quality of ASL images, 7 cases were classified as ASL dominant, and 17 cases were classified as CE dominant. The histological diagnoses of ASL dominant cases were LGG in 3 cases, HGG in 3 cases, and PCNSL in one case. Those of CE dominant cases were HGG in 10 cases, metastasis in 5 cases, and PCNSL in 2 cases. All cases with brain metastasis were classified as CE dominant., Conclusion: The high signal intensity outside the area of contrast enhancement is probably caused by increased perfusion or vascular proliferation, which indicates the presence of glioma or PCNSL and not metastasis. This finding indicates a new utility for ASL images in the diagnosis of brain tumors as a supplement to the conventional measurement of perfusion obtained from ASL images.
- Published
- 2015
- Full Text
- View/download PDF
42. Craniotomy for cerebellar hemangioblastoma excision in a patient with von Hippel-Lindau disease complicated by uncontrolled hypertension due to pheochromocytoma.
- Author
-
Mizobuchi Y, Kageji T, Tadashi Y, and Nagahiro S
- Abstract
Introduction: This report describes a patient with Von Hippel-Lindau (VHL) syndrome and uncontrolled hypertension due to pheochromocytoma who underwent craniotomy for the excision of a cerebellar hemangioblastoma combined with a laparoscopic adrenalectomy., Case Report: A 31-year-old man presented with severe headache. MRI showed areas of abnormal enhancement in the left cerebellum that were determined to be hemangioblastoma with mass effect and obstructive hydrocephalus. His blood pressure rose abruptly and could not be controlled. CT of the abdomen revealed bilateral suprarenal tumors, and the patient was diagnosed as having VHL syndrome.On the third day, he presented with increasing headache, a decreased level of consciousness, and hemiparesis. We were not able to perform an craniotomy because abdominal compression in the prone or sitting position resulted in severe hypertension. We performed ventricular drainage to control his ICP. On the fifth day, we first performed a bilateral laparoscopic adrenalectomy to control ICP and then moved the patient to the prone position before performing a craniotomy to remove the left cerebellar hemangioblastoma. DISCU: ssion & conclusion In patients with pheochromocytoma, the effects of catecholamine oversecretion can cause significant perioperative morbidity and mortality, but these can be prevented by appropriate preoperative medical management. When carrying out an excision of cerebellar hemangioblastomas in patients with intracranial hypertension complicated by abnormal hypertension due to pheochromocytoma whose blood pressure is not sufficiently controlled, tumor resection of the pheochromocytoma prior to cerebellar hemangioblastoma excision in the same surgery may prevent increased ICP and reduce perioperative risk., (Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
43. Atypical teratoid rhabdoid tumor in the cavernous sinus of a toddler presenting with oculomotor nerve palsy.
- Author
-
Inoue N, Watanabe H, Okamura K, Sakaki M, Kageji T, Nagahiro S, and Kagami S
- Subjects
- Female, Humans, Infant, Magnetic Resonance Imaging, Cavernous Sinus pathology, Neoplasms, Vascular Tissue complications, Oculomotor Nerve Diseases complications, Rhabdoid Tumor complications
- Abstract
Introduction: Atypical teratoid rhabdoid tumor (ATRT) is a rare, highly malignant, and aggressive tumor of infancy. Although the prognosis of ATRT has been extremely poor, recently, the first prospective study for ATRT demonstrated improvement of prognosis. On the other hands, oculomotor nerve palsy is rare in children and the most frequent etiology is congenital. To our knowledge, only a few ATRT cases presenting with oculomotor nerve palsy have been reported, but ATRT originating from the cavernous sinus (CS) has not yet been reported., Case Report: An 18-month-old girl with right oculomotor nerve palsy was admitted, and a small mass in the right CS was detected with brain MRI. Although she received steroid pulse therapy and antimicrobial therapy, the mass continued to enlarge. One month after admission, the mass was partially resected and diagnosed as ATRT. Multimodal therapy including anthracycline-based chemotherapy, intrathecal therapy, and cranial irradiation was performed. Twenty-nine months after resection, she was alive without tumor relapse, but the oculomotor nerve palsy persisted., Conclusion: This is the first reported case of ATRT located in the CS presenting with oculomotor nerve palsy. This case was successfully treated with partial removal of the tumor, a new chemotherapy regimen for ATRT and cranial X-ray irradiation.
- Published
- 2014
- Full Text
- View/download PDF
44. Nine-year interval recurrence after treatment of boron neutron capture therapy in a patient with glioblastoma: a case report.
- Author
-
Okazaki T, Kageji T, Mizobuchi Y, Miyamoto T, and Nagahiro S
- Subjects
- Brain Neoplasms diagnosis, Female, Glioblastoma diagnosis, Humans, Longitudinal Studies, Treatment Outcome, Young Adult, Brain Neoplasms radiotherapy, Glioblastoma radiotherapy, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local radiotherapy
- Abstract
Boron neutron capture therapy (BNCT) has been reported to be effective in the patients with glioblastoma multiforme (GBM). Median survival time (MST) of GBM patients treated with BNCT is approximately two years. GBM patients surviving 2 or 3 years are considered long-term survivors. In general, most recurrences are local and dissemination is rare. We report an unusual patient with three recurrences; the first and the second recurrences were local, and the third recurrence was dissemination nine years after BNCT., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
45. Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: comparison of clinical results obtained with BNCT and conventional treatment.
- Author
-
Kageji T, Nagahiro S, Mizobuchi Y, Matsuzaki K, Nakagawa Y, and Kumada H
- Subjects
- Adolescent, Adult, Aged, Brain Neoplasms mortality, Child, Glioblastoma mortality, Humans, Middle Aged, Survival Rate, Boron Neutron Capture Therapy, Brain Neoplasms radiotherapy, Glioblastoma radiotherapy
- Abstract
The purpose of this study was to evaluate the clinical outcome of boron neutron capture therapy (BNCT) and conventional treatment in patients with newly diagnosed glioblastoma. Since 1998 we treated 23 newly-diagosed GBM patients with BNCT without any additional chemotherapy. Their median survival time was 19.5 months; the 2-, 3-, and 5-year survival rates were 31.8%, 22.7%, and 9.1%, respectively. The clinical results of BNCT in patients with GBM are similar to those of recent conventional treatments based on radiotherapy with concomitant and adjuvant temozolomide.
- Published
- 2014
- Full Text
- View/download PDF
46. [Differential diagnosis of and therapy for anaplastic astroblastoma: case report and review of the literature].
- Author
-
Kurashiki Y, Kageji T, Mizobuchi Y, Satomi J, Satoh K, Hirose T, and Nagahiro S
- Subjects
- Adult, Brain Neoplasms diagnosis, Chemoradiotherapy, Female, Humans, Magnetic Resonance Imaging methods, Neoplasms, Neuroepithelial diagnosis, Treatment Outcome, Brain Neoplasms pathology, Brain Neoplasms therapy, Diagnosis, Differential, Neoplasms, Neuroepithelial pathology, Neoplasms, Neuroepithelial therapy
- Abstract
Astroblastomas are rare glial tumors. We report a case of 33-year-old woman with high-grade astroblastoma with hypervascularity. She had a one-month history of right visual disturbance and papillar edema. MRI revealed a lobulated mass with cysts and flow voids in the right superficial frontal lobe, a phenomenon described as "bubbly appearance". Right carotid angiography demonstrated marked tumor stain and early venous filling. MR spectroscopy showed an increase in myoinositol and the choline/creatine ratio, and decreased N-acetyl aspartate. The lipid and lactate level was not increased. The well-circumscribed tumor was totally resected. Histological examination showed perivascular pseudorosettes and hyalinization of blood vessels with high cellularity, anaplastic nuclear features, focal necrosis, mitosis, and endothelial proliferation. Immunohistochemically, glial fibrillary acidic protein and S-100 protein were intensely positive and the MIB-1 labeling index was high(20%)in the tumor cells. Based on these findings, a diagnosis of high-grade astroblastoma was made. The patient received postoperative radiotherapy and chemotherapy with temozolomide and suffered no relapse in the course of 3 years after surgery. Characteristically, astroblastomas manifest a "bubbly appearance" and a lobulated mass on MRI scans. As these tumors tend to be hypervascular, angiograms are useful for designing the operative strategy. However, their low-or high grade is difficult to ascertain preoperatively based on MRI-, MRS-, and DSA findings. The standard therapy for high-grade astroblastoma is total resection and postoperative radiation therapy. As the incidence of tumor recurrence is high, we recommend additional chemotherapy with TMZ.
- Published
- 2013
47. Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma.
- Author
-
Okazaki T, Kageji T, Kuwayama K, Kitazato KT, Mure H, Hara K, Morigaki R, Mizobuchi Y, Matsuzaki K, and Nagahiro S
- Subjects
- Adaptor Proteins, Signal Transducing physiology, Apoptosis physiology, Base Sequence, Blotting, Western, Brain Neoplasms pathology, Cell Line, Tumor, DNA Primers, Dacarbazine pharmacology, Glioblastoma pathology, Humans, Phosphoproteins physiology, Promyelocytic Leukemia Protein, Real-Time Polymerase Chain Reaction, Temozolomide, Transcription Factors, Tumor Protein p73, YAP-Signaling Proteins, Apoptosis drug effects, Brain Neoplasms metabolism, DNA-Binding Proteins physiology, Dacarbazine analogs & derivatives, Glioblastoma metabolism, Interferon-beta pharmacology, Nuclear Proteins metabolism, Nuclear Proteins physiology, Tumor Suppressor Proteins metabolism, Tumor Suppressor Proteins physiology, Up-Regulation
- Abstract
Interferon-beta (IFN-β) is reported to augment anti-tumor effects by temozolomide in glioblastoma via down-regulation of MGMT. Promyelocytic leukemia (PML), a gene induced by IFN-β, is a tumor suppressor. Here, we report for the first time that in combination therapy, an IFN-β-induced increase in endogenous PML contributes to anti-tumor effects in p53 wild- and mutant glioma cells in a xenograft mice model. The increased PML promoted the accumulation of p73, a structural and functional homolog of p53, to fuse the coactivator Yes-associated-protein in the PML nuclear bodies. The adjuvant therapy targeted at PML may be a promising therapeutic strategy for glioblastoma., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
48. Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
- Author
-
Ishizawa K, Hirose T, Sugiyama K, Kageji T, Nobusawa S, Homma T, Komori T, and Sasaki A
- Subjects
- Adult, Astrocytoma genetics, Astrocytoma pathology, Brain Neoplasms genetics, Brain Neoplasms pathology, DNA Mutational Analysis, Female, Humans, Isocitrate Dehydrogenase genetics, Male, Middle Aged, Oligodendroglioma genetics, Oligodendroglioma pathology, Astrocytoma metabolism, Brain Neoplasms metabolism, Isocitrate Dehydrogenase metabolism, Oligodendroglioma metabolism
- Abstract
Glioneuronal tumor with neuropil-like islands (GTNI) is featured by "neuropil-like islands (NIs)" within dominating astroglial components. Isocitrate dehydrogenase (IDH) mutations, particularly IDH1 R132H (G395A), are found in WHO Grade II and III diffuse gliomas as well as secondary, but not primary, glioblastomas. We reviewed 5 cases of GTNI, and assessed histology and immunohistochemistry with various antibodies, including those for IDH1 R132H, as well as direct DNA sequencing for IDH1 G395A. NIs were variable in morphology, and constantly synaptophysin-positive and glial fibrillary acidic protein-negative. The glioma components were primary glioblastoma in 2 cases, anaplastic astrocytoma in 1 and anaplastic oligoastrocytoma in 2. The IDH1 R132H was expressed in the 2 cases with oligoastrocytoma: In 1, NIs and the astrocytoma-like area as well as the oligodendroglioma-like area were positive. In the other, only the oligodendrogliomalike area was positive. The mutation analysis performed on the latter case with DNA separately sampled from the oligodendroglioma- like area and the astrocytoma-like area detected IDH1 G395A in both areas. We have shown diverse pathologic aspects of GTNI. Also, we have shown that the expression of IDH1 R132H in GTNI is largely concordant with that in diffuse gliomas, and that it can be dependent on each histologic component although the mutant IDH1 gene is ubiquitously present within the tumor.
- Published
- 2012
- Full Text
- View/download PDF
49. Activation of signal transducer and activator of transcription-3 by a peroxisome proliferator-activated receptor gamma agonist contributes to neuroprotection in the peri-infarct region after ischemia in oophorectomized rats.
- Author
-
Kinouchi T, Kitazato KT, Shimada K, Yagi K, Tada Y, Matsushita N, Sumiyoshi M, Satomi J, Kageji T, and Nagahiro S
- Subjects
- Animals, Apoptosis genetics, Basal Ganglia pathology, Brain pathology, Brain Ischemia pathology, Caspase 3 metabolism, Cell Nucleus metabolism, Cerebral Infarction pathology, DNA genetics, Estrogen Receptor alpha metabolism, Female, Pioglitazone, Protein Transport, Rats, Rats, Wistar, Response Elements, Transcriptional Activation drug effects, Brain Ischemia drug therapy, Cerebral Infarction drug therapy, Neuroprotective Agents, Ovariectomy, PPAR gamma agonists, STAT3 Transcription Factor genetics, STAT3 Transcription Factor metabolism, Thiazolidinediones therapeutic use
- Abstract
Background and Purpose: The role of the phosphorylated signal transducer and activator of transcription-3 (p-STAT3) after cerebral ischemia by the peroxisome proliferator-activated receptor γ (PPARγ) agonist pioglitazone (PGZ) remains controversial. Whether the increase in p-STAT3 by estrogen is mediated by the estrogen receptor α is also obscure. We examined the role of p-STAT3, PPARγ, and estrogen receptor α against ischemic brain damage after PGZ treatment., Methods: Female Wistar rats subjected or not subjected to bilateral oophorectomy were injected with 1.0 or 2.5 mg/kg PGZ 2 days, 1 day, and 1 hour before 90-minute middle cerebral artery occlusion-reperfusion and compared with vehicle-control rats., Results: The cortical infarct size was larger in ovariectomized than in nonovarietomized rats; it was reduced by PGZ treatment. Inversely with the reduction of the infarct size, PPARγ, and p-STAT3 but not estrogen receptor α in the peri-infarct area were increased in PGZ-treated compared with vehicle-control rats. The increase in PPARγ and p-STAT3 was associated with the transactivation of antiapoptotic and survival genes and the reduction of caspase-3 in this area. Inhibitors of PPARγ or STAT3 abolished the PGZ-induced neuroprotection and the increase in p-STAT3. More importantly, p-STAT3 increased by PGZ was bound to PPARγ and the complex translocated to the nucleus to dock to the response element through p-STAT3., Conclusions: Our findings suggest that the activation in the peri-infarct region of p-STAT3 and PPARγ by PGZ is essential for neuroprotection after ischemia and that PGZ may be of benefit even in postmenopausal stroke patients.
- Published
- 2012
- Full Text
- View/download PDF
50. Statins promote the growth of experimentally induced cerebral aneurysms in estrogen-deficient rats.
- Author
-
Tada Y, Kitazato KT, Yagi K, Shimada K, Matsushita N, Kinouchi T, Kanematsu Y, Satomi J, Kageji T, and Nagahiro S
- Subjects
- Animals, Apoptosis, Cells, Cultured, Disease Models, Animal, Endothelial Cells drug effects, Endothelial Cells metabolism, Endothelial Cells pathology, Female, Humans, Hypertension complications, Hypertension metabolism, Hypertension pathology, Intracranial Aneurysm etiology, Intracranial Aneurysm metabolism, Nitric Oxide Synthase Type III metabolism, Rats, Rats, Sprague-Dawley, Brain drug effects, Brain pathology, Estrogens deficiency, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Intracranial Aneurysm pathology, Pravastatin pharmacology, Simvastatin pharmacology
- Abstract
Background and Purpose: The pathogenesis of cerebral aneurysms is linked to inflammation, degradation of the extracellular matrix, and vascular wall apoptosis. Statins exert pleiotropic effects on the vasculature, independent of their cholesterol-lowering properties. To explore the detailed pathogenesis of cerebral aneurysms, we examined their progression in a rat model and studied whether statins prevent their initiation and growth., Methods: Cerebral aneurysms were induced in female rats subjected to hypertension, increased hemodynamic stress, and estrogen deficiency. The development of aneurysm was assessed morphologically on corrosion casts. The effects of pravastatin (5, 25, or 50 mg/kg per day) and of simvastatin (5 mg/kg per day) on their aneurysms were studied. Human brain endothelial cells were also used to determine the effects of pravastatin., Results: Pravastatin (5 mg/kg per day) reduced endothelial damage and inhibited aneurysm formation; there was an association with increased endothelial nitric oxide synthase (eNOS) levels and a decrease in human brain endothelial cell adhesion molecules. Unexpectedly, 25 mg/kg per day and 50 mg/kg per day pravastatin and 5 mg/kg per day simvastatin promoted aneurysmal growth, and high-dose pravastatin induced aneurysmal rupture. The deleterious effects exerted by these statins were associated with an increase in apoptotic caspase-3 levels and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells, suggesting that statins exert bidirectional effects., Conclusions: Our results provide the first evidence that cerebral aneurysm growth is partly associated with apoptosis and issue a warning that statins exert bidirectional effects on cerebral aneurysms. Additional intensive research is necessary to understand better their mechanisms and to identify patients in whom the administration of statins may elicit deleterious effects.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.